Treatment of patients with colorectal cancer: Emphasis on liver metastases Journal Article
| Authors: | Gallagher, D.; Kemeny, N. |
| Article Title: | Treatment of patients with colorectal cancer: Emphasis on liver metastases |
| Abstract: | The treatment of colorectal liver metastases has progressed considerably in recent years. Coordinated multidisciplinary management of patients on clinical trials has resulted in 5-year survival rates exceeding 50%, and for certain patients cure is now a realistic goal. For all patients, the approval of six new drugs has contributed to an increase in median survival from 6 months to over 20 months. Recent molecular discoveries promise an era of tailored therapy in which only patients known to benefit will be treated, an approach that will enable more efficient use of the already stretched resources. Clinical trials continue to investigate different combinations and methods of administering approved therapies, but if the progress of the past decade is to be replicated it is imperative that we embrace innovative treatment strategies and novel trial designs. In this review, we highlight the developments that have improved survival for patients with colorectal liver metastases and discuss the many issues that challenge further progress. © 2009 Informa UK Ltd All rights reserved. |
| Keywords: | vasculotropin; cancer chemotherapy; cancer survival; disease-free survival; survival rate; overall survival; clinical trial; mortality; neutropenia; review; postoperative period; bevacizumab; fluorouracil; cancer combination chemotherapy; diarrhea; drug dose reduction; drug withdrawal; side effect; treatment duration; unspecified side effect; liver neoplasms; drug targeting; capecitabine; cancer patient; disease free survival; postoperative care; methotrexate; neurotoxicity; antineoplastic agent; colorectal cancer; metabolism; metastasis; progression free survival; quality of life; multiple cycle treatment; vomiting; antineoplastic combined chemotherapy protocols; dehydration; epidermal growth factor receptor; genetic association; dexamethasone; pathology; cetuximab; cancer therapy; irinotecan; panitumumab; drug dose escalation; rash; colorectal neoplasms; survival time; liver metastasis; preoperative period; clinical trials, phase iii as topic; thromboembolism; colorectal tumor; folinic acid; adjuvant chemotherapy; liver tumor; liver resection; hepatectomy; phase 3 clinical trial; intestine perforation; oncogene k ras; oxaliplatin; floxuridine; convalescence; hepatic metastases; fluoropyrimidine; fluoropyrimidine derivative; bilirubin blood level; cost of illness |
| Journal Title: | Expert Opinion on Pharmacotherapy |
| Volume: | 10 |
| Issue: | 1 |
| ISSN: | 1465-6566 |
| Publisher: | Informa Healthcare |
| Date Published: | 2009-01-01 |
| Start Page: | 109 |
| End Page: | 124 |
| Language: | English |
| DOI: | 10.1517/14656560802631301 |
| PUBMED: | 19236185 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Export Date: 30 November 2010" - "CODEN: EOPHF" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work